STAAR Surgical Company (STAA)

STAAR Surgical's stock has been impacted by several key events in the past six months. Preliminary Q1 2026 revenue exceeding $90 million led to a surge in its stock price, attributed to robust demand in China and continued sales growth in the Americas. The FDA approved an expanded age range for its EVO/EVO+ Visian Implantable Collamer Lenses, expected to broaden the potential U.S. market. However, the company faced challenges in 2025, with revenue declining by 23.7%, primarily due to a drop in the Asia Pacific region. Profitability also worsened, leading some analysts to maintain a "Sell" rating on the stock in early 2026. In January 2026, the company underwent a governance reset following the rejection of an all-cash merger with Alcon. As of May 8, 2026, the stock price had risen but experienced a loss over the preceding four weeks.

Demand for refractive surgery in 2025 was "materially less volatile than in prior years," indicating a stabilization in demand. STAAR Surgical remains optimistic about long-term opportunities in China and other emerging markets in Asia. The global epidemics of myopia and dry eye disease continue to drive the refractive surgery market.

STAAR Surgical Co. manufactures implantable lenses for the eye and associated delivery systems, operating in the healthcare sector, specifically in the medical devices and instruments industry. Its primary products are Implantable Collamer Lenses (ICLs), particularly the EVO family of ICLs, used in refractive surgery. The company has largely phased out IOLs for cataract surgery, with ICLs accounting for nearly all of its revenue. STAAR Surgical has been dedicated solely to ophthalmic surgery for over 40 years.

STAAR Surgical has a significant global presence, selling its products in over 85 countries and maintaining direct distribution in key markets. The company's global administrative offices and principal manufacturing facility are located in Monrovia, California, with other facilities in California and Switzerland. A substantial portion of the company's revenue is generated from foreign sales, with a significant portion coming from China.

STAAR Surgical has maintained a strong brand reputation, particularly through its innovative EVO ICL product line. The company announced it had surpassed 4 million Implantable Collamer Lenses sold globally, highlighting a growing preference for lens-based vision correction. The company has also engaged in patient awareness campaigns to educate potential U.S. patients about the EVO ICL procedure.

Institutional investors hold a dominant position in STAAR Surgical's ownership. Major institutional owners include Broadwood Capital Inc, BlackRock, Inc., and Vanguard Group Inc. Broadwood Partners LP is identified as the largest individual shareholder.